Hints and tips:
...The Korean Wave opens September 24, V&A ‘Make, Break, Remix: The Rise of K-Style’ by Fiona Bae, (Thames & Hudson), will be published in the UK & Ireland on 22 September 2022...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Among other assignments, he advised Time Warner on its $80bn merger with AT&T, and represented Wyeth during its $68bn sale to Pfizer....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...unlovable, nominally American dealmaker wanted to buy a rival that The Economist calculated to be only about 12 per cent “British”, based on factors such as employees’ nationalities and where it sells its wares...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...But the share price jump at Crucell, following its revelation last week of “friendly discussions” with Wyeth of the US, suggests that for those with decent wares, the downturn offers a seller’s market for...
...But the share price jump at Crucell, after its revelation last week of “friendly discussions” with Wyeth of the US, suggests that for those with decent wares, the downturn still offers a seller’s market...
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
...The software is being tested by a small handful of customers, including Pfizer, the pharmaceuticals group....
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
International Edition